Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.

Grade Last Price % Change Price Change
C 5.09 3.04% 0.15
VNDA closed up 3.04 percent on Friday, November 22, 2024, on approximately normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Flat

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 20 DMA Bullish 3.04%
Fell Below 20 DMA Bearish 3.88%
MACD Bearish Signal Line Cross Bearish 3.88%
NR7 Range Contraction 3.88%
NR7-2 Range Contraction 3.88%
Narrow Range Bar Range Contraction 3.88%
Doji - Bullish? Reversal 3.88%
Down 3 Days in a Row Weakness 3.88%

   Recent Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vanda Pharmaceuticals Inc. Description

Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Alcohol Clinical Development Oncology Organic Compounds Chemical Compounds Chemotherapy Schizophrenia Depression Central Nervous System Disorders Major Depressive Disorder Nervous System Disorders Depressive Disorder Sleep Disorders Pyridines Insomnia Nausea Treatment Of Major Depressive Disorder Sedatives Treatment Of Schizophrenia Treatment Of Central Nervous System Disorders Pruritus Chemotherapy Induced Nausea Fanapt Iloperidone

Is VNDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.75
52 Week Low 3.46
Average Volume 650,815
200-Day Moving Average 4.98
50-Day Moving Average 4.80
20-Day Moving Average 4.96
10-Day Moving Average 5.11
Average True Range 0.21
RSI (14) 55.56
ADX 25.46
+DI 31.32
-DI 18.95
Chandelier Exit (Long, 3 ATRs) 4.92
Chandelier Exit (Short, 3 ATRs) 5.09
Upper Bollinger Bands 5.45
Lower Bollinger Band 4.47
Percent B (%b) 0.63
BandWidth 19.64
MACD Line 0.07
MACD Signal Line 0.08
MACD Histogram -0.0127
Fundamentals Value
Market Cap 292.87 Million
Num Shares 57.5 Million
EPS 0.04
Price-to-Earnings (P/E) Ratio 127.25
Price-to-Sales 1.24
Price-to-Book 0.44
PEG Ratio -2.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.48
Resistance 3 (R3) 5.46 5.31 5.42
Resistance 2 (R2) 5.31 5.21 5.32 5.39
Resistance 1 (R1) 5.20 5.15 5.26 5.22 5.37
Pivot Point 5.05 5.05 5.08 5.06 5.05
Support 1 (S1) 4.94 4.95 5.00 4.96 4.81
Support 2 (S2) 4.79 4.89 4.80 4.79
Support 3 (S3) 4.68 4.79 4.77
Support 4 (S4) 4.70